Predictors for Risk for Developing Taxane-Induced Peripheral Neuropathy

Share this content:

the Cancer Therapy Advisor take:

Single-nucleotide polymorphisms (SNPs) and genetically determined race were identified as two significant biomarkers associated with predicting taxane-induced peripheral neuropathy (TIPN) in patients, according to an article published online in the journal Clinical Cancer Research.

This genome wide association study (GWAS) included 3,431 patients who were a part of the phase 3 adjuvant breast cancer trial, ECOG-5103. In the trial, genotypes were compared with TIPN.

Top SNPs were evaluated for TIPN as candidate validation in a different phase 3 adjuvant breast cancer trial (ECOG-1199).

Results from ECOG-5103 showed that for grade 3 to 4 TIPN, 120 SNPs were identified for patients of European descent (EA) (P<10-4). In ECOG-1199, 30 candidate SNPs were evaluated, however only SNP rs3125923 was determined to have a significant correlation with grade 3 to 4 TIPN (OR: 1.8; P=1.1 x 10-11).

Furthermore, race was determined to be a significant predictor of TIPN in patients of African descent (AA). These patients were at an increased risk of both grades 2 to 4 and grades 3 to 4 TIPN (HR=2.1; P=5.6×10-16 compared to HR=2.6; P=1.1×10-11, respectively).

A trend toward an association between grades 2 to 4 TIPN and a SNP in FCAMR (rs1856746) was observed in AA patients from ECOG-5103 (OR=5.5; P=1.6 x 10-7).

A Call for Improving the Quality of Cancer Care in Geriatric Patients
Single-nucleotide polymorphisms (SNPs) and genetically determined race were identified as two significant biomarkers associated with predicting taxane-induced peripheral neuropathy (TIPN) in patients
Taxane induced peripheral neuropathy (TIPN) is an important survivorship issue for many cancer patients. Currently, there are no clinically implemented biomarkers to predict which patients might be at increased risk for TIPN.
READ FULL ARTICLE From clincancerres.aacrjournals.org

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters